<DOC>
	<DOCNO>NCT02051738</DOCNO>
	<brief_summary>The purpose study evaluate effect food bioavailability ( much medication blood ) mebendazole single 500 mg oral dose fast-disintegrating chewable tablet formulation mebendazole healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Effect Food Bioavailability Mebendazole From Fast-Disintegrating Chewable Formulation Mebendazole Healthy Participants</brief_title>
	<detailed_description>This open-label ( participant study physician know participant get ) , randomize ( like flip coin ) , single-center , single-dose , 2-way crossover ( method use switch participant one treatment arm another clinical study ) study approximately 16 healthy adult participant . Participants receive study medication feed state first later fast state vice versa . The study consist 3 phase : screen phase approximately 3 week , open-label treatment phase consist two 6-day treatment period ( Treatment period 1 2 ) 7- 10 day washout Day 1 treatment period , safety follow-up phase occur 7 10 day last study-related procedure Day 5 Treatment Period 2 . The study physician check participant 's general health study . Total duration study participant approximately 48 day .</detailed_description>
	<mesh_term>Mebendazole</mesh_term>
	<mesh_term>Piperazine</mesh_term>
	<mesh_term>Piperazine citrate</mesh_term>
	<criteria>Must sign informed consent document Woman must postmenopausal , surgically sterile , abstinent , , sexually active , practice effective method birth control entry throughout study Woman must negative serum human chorionic gonadotropin pregnancy test screening ; negative urine pregnancy test Day 1 treatment period Man must agree use adequate contraception method deem appropriate investigator donate sperm study 3 month receive last dose study medication Blood pressure ( participant sit 5 minute ) 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude subject could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center Day 1 Treatment Period deem appropriate investigator Clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram screen admission study center Day 1 Treatment Period deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol , oral contraceptive hormonal replacement therapy within 14 day dose treatment period Positive test drug abuse , cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine , hallucinogen barbiturate screen Day 1 treatment period History clinically significant allergy , especially know hypersensitivity intolerance lactose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Mebendazole</keyword>
	<keyword>Fast-Disintegrating Chewable Formulation</keyword>
	<keyword>Bioavailability</keyword>
</DOC>